Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (646) 481-9832 Not Applicable OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40384 __________________________________________________________ TOURMALINE BIO, INC. (Exact name of Registrant a ...

Back to Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 1-2958 HUBBELL INCORPORATED (Exact name of registrant as specified in its charter) (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (312) 630-1900 Commission file number 001-14157 TEL ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) | Title of each class | Trading Symbol(s) | Name of each exchange on which | | --- | ...

Exhibit 99.1 Vislink Reports Fourth Quarter and Full Year 2024 Financial and Operational Results Mt. Olive, NJ — May 2, 2025 — Vislink Technologies, Inc. ("Vislink" or the "Company") (OTCQB: VISL), a global technology leader in the capture, delivery, and management of high-quality live video and associated data in the media and entertainment, law enforcement, and defense markets, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 and Recent Company Highl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOG ...

Financial Performance - AAM's sales for Q1 2025 were $1.41 billion, down from $1.61 billion in Q1 2024, reflecting a decrease in overall volumes [4]. - Net income for Q1 2025 was $7.1 million, or 0.5% of sales, compared to $20.5 million, or 1.3% of sales in Q1 2024 [5]. - Adjusted EBITDA for Q1 2025 was $177.3 million, or 12.6% of sales, down from $205.6 million, or 12.8% of sales in Q1 2024 [6]. - Net sales for Q1 2025 were $1,411.3 million, a decrease of 12.1% compared to $1,606.9 million in Q1 2024 [28]. - Gross profit for Q1 2025 was $173.9 million, down from $198.5 million in Q1 2024, reflecting a gross margin of 12.3% [28]. - Operating income decreased to $42.7 million in Q1 2025 from $77.0 million in Q1 2024, representing a decline of 44.5% [28]. - Net income for Q1 2025 was $7.1 million, significantly lower than $20.5 million in Q1 2024, resulting in diluted earnings per share of $0.06 compared to $0.17 [28][36]. - Adjusted EBITDA for Q1 2025 was $177.3 million, down from $205.6 million in Q1 2024, indicating a decrease of 13.7% [34]. - Free cash flow for Q1 2025 was negative at $(12.8) million, an improvement from $(27.1) million in Q1 2024 [40]. Cash Flow and Outlook - AAM's net cash provided by operating activities for Q1 2025 was $55.9 million, significantly higher than $17.8 million in Q1 2024 [6]. - Adjusted free cash flow for Q1 2025 was $(3.9) million, an improvement from $(21.4) million in Q1 2024 [7]. - AAM's updated financial outlook for 2025 targets sales between $5.65 billion and $5.95 billion, down from a previous range of $5.8 billion to $6.05 billion [17]. - The company is targeting Adjusted EBITDA in the range of $665 million to $745 million for 2025, revised from $700 million to $760 million [17]. - AAM anticipates Adjusted free cash flow for 2025 to be between $165 million and $215 million, down from a prior target of $200 million to $230 million [17]. - Net cash provided by operating activities is estimated to be between $375 million and $425 million [45]. - Full year 2025 targeted Free Cash Flow is expected to be between $75 million and $125 million [45]. - Full year 2025 targeted Adjusted Free Cash Flow is anticipated to range from $165 million to $215 million [45]. Assets and Liabilities - Total assets increased to $5,139.4 million as of March 31, 2025, compared to $5,059.9 million at the end of 2024 [30]. - Total liabilities rose to $4,543.1 million as of March 31, 2025, up from $4,497.1 million at the end of 2024 [30]. Costs and Expenses - The company reported a restructuring and acquisition-related cost of $19.7 million in Q1 2025, compared to $2.5 million in Q1 2024 [28]. - Interest expense for the period is projected to be between $170 million and $180 million [45]. - Depreciation and amortization costs are expected to remain constant at $455 million [45]. - Restructuring-related costs are estimated at $25 million for the year [45]. - Dowlais acquisition-related costs are projected to be $65 million [45]. - Income tax expense is expected to be between $35 million and $50 million [45]. Production and Sales Segments - North American light vehicle production is estimated to be approximately 14.0 to 15.1 million units for 2025 [17]. - Segment sales for Driveline were $957.8 million in Q1 2025, down from $1,106.4 million in Q1 2024, while Metal Forming sales decreased to $575.8 million from $644.1 million [42].

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26719 MERCANTILE BANK CORPORATION (Exact name of registrant as specified in its charter) Michigan 38-3360865 (State or other jurisdictio ...